Supplementary Marterial 1. Summary of gastrointestinal disorders, nausea, and vomiting in Clinical Trial ONO-2745-05. (at least 10% of patients; SAF). Values are number (proportion).

	Remimazolam 6 mg/kg/h (n = 150)		Remimazolam 12 mg/kg/h (n = 150)	
Event*	**AE**	**ADR**	**AE**	**ADR**
Gastrointestinal disorders	49 (32.7%)	19 (12.7%)	38 (25.3%)	14 (9.3%)
Nausea	28 (18.7%)	11 (7.3%)	25 (16.7%)	10 (6.7%)
Vomiting	19 (12.7%)	7 (4.7%)	26 (17.3%)	11 (7.3%)

*Coded using Preferred Term and System Organ Class according to the Medical Dictionary for Regulatory Activities (MedDRA)
ADR, adverse drug reaction; AE, adverse event; SAF, safety population

The authors translated the table from Japanese to English with the approval of the rights holders.

Pharmaceuticals and Medical Devices Agency. Remimazolam besilate, Summary of Application Materials. Tokyo: Government [Internet] c2004 [2021 Oct 19], p160-259, Japanese. Available from https://www.pmda.go.jp/drugs/2020/P20200120002/index.html.